The traditional view of neurodegenerative diseases has focused on protein aggregate accumulation in the brain. However, new evidence suggests that systemic metabolic and inflammatory signals play a crucial role in brain aging. The protein GDF15, also known as MIC-1, a cytokine present in the bloodstream, is now linked to the long-term risk of developing dementia.
GDF15 belongs to the transforming growth factor beta (TGF-) superfamily. It is normally detected in low amounts but increases significantly in response to cellular stress, systemic inflammation, or tissue damage. While traditionally considered a general sensor of biological stress and an appetite regulator, recent findings indicate that its blood levels in middle age might influence the brain's immune microenvironment decades later.
Follow-ups of human cohorts over 15 to 25 years have observed that a single blood measurement of GDF15 in individuals aged 40 to 60 is associated with a subsequent risk of dementia. This association is stronger for vascular dementia, where elevated GDF15 levels can double the risk, compared to Alzheimer's disease (AD), where the risk increase is moderate (20%). Brain imaging corroborates this link, showing that high GDF15 levels are associated with more white matter lesions and damage to small blood vessels.
Cerebrospinal fluid analysis reveals that high blood GDF15 concentrations coincide with an inflammatory pattern in the central nervous system, characterized by increased chemokines and activated vascular endothelial cells. In vitro experiments suggest that exposure to GDF15 alters the metabolic and immune networks of macrophages, affecting antiviral response and free iron clearance capacity.
Despite these findings, researchers emphasize caution. The association does not imply direct causality, and genetic evidence is mixed. Experiments were conducted on macrophages derived from peripheral blood, not in vivo human microglia. Therefore, GDF15 is not yet considered a routine screening test or a guide for preventive treatments, pending determination of its predictive value against known cardiovascular risk factors.
Nevertheless, the study opens hypotheses for exploring the modulation of GDF15 or its metabolic pathways as a strategy to slow neurovascular decline. Blocking drugs for this molecule could be tested in preclinical models, although systemic inhibition requires rigorous analysis to avoid side effects. The work consolidates the importance of bodily immune signals as early diagnostic markers and potential therapeutic targets for cognitive health.
